NEW YORK (GenomeWeb) – NimaGen, a Dutch molecular biology research tools firm, said today that it has licensed one-step PCR technology employing reverse complement probes from the Salisbury NHS Foundation Trust in the UK.
NimaGen said that it will use the technology to develop and market new kits and panels for next-generation sequencing.
Specific terms of the agreement call for NimaGen to receive a worldwide license to the technology for research applications including the development and sale of products for sample tracking and authentication within laboratories, high-throughput screening, and diagnostic research.
Reverse complement PCR technology enables the combined generation and flexible tagging of amplicon constructs from a target sequence or sequences in a single, closed-tube amplification and indexing reaction.